Climb Bio (NASDAQ:CLYM – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, Zacks reports.
Climb Bio Trading Down 0.8 %
NASDAQ:CLYM traded down $0.01 on Wednesday, reaching $1.29. The company’s stock had a trading volume of 66,666 shares, compared to its average volume of 374,272. Climb Bio has a 12-month low of $1.20 and a 12-month high of $11.55. The company has a 50 day moving average of $1.59. The firm has a market capitalization of $86.72 million, a price-to-earnings ratio of -0.61 and a beta of -0.19.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on CLYM. Leerink Partnrs raised shares of Climb Bio to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Climb Bio in a research note on Monday, December 2nd. They issued an “outperform” rating and a $10.00 price target for the company.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Read More
- Five stocks we like better than Climb Bio
- How to trade using analyst ratings
- Energy Transfer: Powering Data With Dividends and Diversification
- Technology Stocks Explained: Here’s What to Know About Tech
- Qualcomm Stock Is Coiling for a Breakout
- ESG Stocks, What Investors Should Know
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
